¼¼°èÀÇ »óÇǼºÀåÀÎÀÚ ¼ö¿ëü-ºñ¼Ò¼¼Æ÷Æó¾Ï(EGFR-NSCLC) ½ÃÀå
Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC)
»óǰÄÚµå : 1797270
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 283 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

»óÇǼºÀåÀÎÀÚ ¼ö¿ëü-ºñ¼Ò¼¼Æ÷Æó¾Ï(EGFR-NSCLC) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 101¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 75¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â »óÇǼºÀåÀÎÀÚ ¼ö¿ëü-ºñ¼Ò¼¼Æ÷Æó¾Ï(EGFR-NSCLC) ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£¿¡ CAGR 5.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 101¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿À½Ã¸ÓƼ´ÕÀº CAGR 5.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 45¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¤·ÎƼ´Õ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 3.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 20¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ »óÇǼºÀåÀÎÀÚ ¼ö¿ëü-ºñ¼Ò¼¼Æ÷Æó¾Ï(EGFR-NSCLC) ½ÃÀåÀº 2024³â¿¡ 20¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024³âºÎÅÍ 2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 8.3%·Î ¼ºÀåÇÏ¿© 2030³â±îÁö 20¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.5%¿Í 5.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ EGFR-ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC) ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

EGFR »óŰ¡ ºñ¼Ò¼¼Æ÷Æó¾Ï Ä¡·á Àü·«¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´Â°¡?

»óÇǼ¼Æ÷¼ºÀåÀÎÀÚ¼ö¿ëü(EGFR) µ¹¿¬º¯ÀÌ´Â ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC), ƯÈ÷ ¼±¾Ï ¾ÆÇü¿¡¼­ Áß¿äÇÑ ¹ÙÀÌ¿À¸¶Ä¿ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ µ¹¿¬º¯ÀÌ´Â EGFR ½ÅÈ£Àü´Þ °æ·ÎÀÇ °úȰ¼ºÈ­·Î À̾îÁ® Á¶ÀýµÇÁö ¾Ê´Â ¼¼Æ÷ºÐ¿­°ú Á¾¾ç ¼ºÀåÀ» ÃËÁøÇÕ´Ï´Ù. À¯·´°ú ¹Ì±¹¿¡¼­´Â ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚÀÇ ¾à 10-15%, ¾Æ½Ã¾Æ¿¡¼­´Â ÃÖ´ë 40%°¡ EGFR µ¹¿¬º¯À̸¦ º¸À̱⠶§¹®¿¡ °³Àκ° ¸ÂÃã Ä¡·á °èȹ¿¡ ºÐÀÚ °Ë»ç°¡ ÇʼöÀûÀÔ´Ï´Ù.

EGFR µ¹¿¬º¯ÀÌÀÇ È®ÀÎÀº ºñÁ¤»óÀûÀÎ EGFR ½ÅÈ£Àü´ÞÀ» ¾ïÁ¦Çϴ ǥÀû Ä¡·áÁ¦, ƯÈ÷ Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦(TKI)ÀÇ »ç¿ëÀ» °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. ÀÌµé ¾àÁ¦´Â ±âÁ¸ Ç×¾ÏÈ­Çпä¹ý¿¡ ºñÇØ ¹«ÁøÇà »ýÁ¸±â°£À» °³¼±ÇÏ°í µ¶¼ºÀ» °¨¼Ò½ÃÄ×½À´Ï´Ù. °ÔÇÇÆ¼´ÕÀ̳ª ¿¤·ÎƼ´Õ°ú °°Àº 1¼¼´ë TKI´Â T790M°ú °°Àº ³»¼º µ¹¿¬º¯À̸¦ ±Øº¹ÇÒ ¼ö ÀÖ´Â ¿À½Ã¸ÓƼ´Õ°ú °°Àº »õ·Î¿î ¾à¹°·Î ´ëüµÇ¾ú½À´Ï´Ù. ±× °á°ú, EGFR °Ë»ç´Â ÇöÀç ÀÓ»ó Á¾¾çÇÐ ¿öÅ©Ç÷ο쿡¼­ ºñ¼Ò¼¼Æ÷Æó¾Ï Áø´ÜÀÇ Ç¥ÁØ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù.

Ç¥Àû Ä¡·á¿Í ³»¼º °ü¸®¸¦ À籸¼ºÇÏ´Â µ¥ ÀÖ¾î ¾î¶² ÁøÀüÀÌ ÀÌ·ç¾îÁö°í Àִ°¡?

ÃÖ±Ù EGFR Ç¥Àû Ä¡·áÀÇ ¹ßÀüÀº ¾à¹° ¼±Åüº Çâ»ó, ³»¼º ±Øº¹, ºÎÀÛ¿ë ÃÖ¼ÒÈ­¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ¿À½Ã¸ÓƼ´Õ°ú °°Àº 3¼¼´ë TKI´Â ÁßÃ߽Űæ°è ÀüÀÌ ¹× ÀÌÀü Ä¡·á¿¡ ´ëÇÑ ÈÄõÀû ³»¼ºÀÌ Àִ ȯÀÚ¿¡¼­ È¿´ÉÀ» º¸À̰í ÀÖ½À´Ï´Ù. ÇöÀç ¾à¹°·Î È¿°úÀûÀ¸·Î ´ëóÇÒ ¼ö ¾ø´Â Èñ±ÍÇÑ EGFR º¯ÀÌ ¹× º¹ÇÕ º¯À̸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â 4¼¼´ë ¾ïÁ¦Á¦¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇà ÁßÀÔ´Ï´Ù.

¾×ü »ý°Ë ±â¼úÀº EGFR µ¹¿¬º¯ÀÌ »óŸ¦ ¸ð´ÏÅ͸µÇÏ°í ³»¼º µ¹¿¬º¯À̸¦ ½Ç½Ã°£À¸·Î °ËÃâÇÏ´Â ºñħ½ÀÀû µµ±¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¿ªµ¿ÀûÀÎ Ä¡·á Á¶Á¤À» °¡´ÉÇÏ°Ô Çϰí, Á¶Á÷ »ý°Ë¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙ¿©ÁÝ´Ï´Ù. TKI¿Í Ç×Ç÷°ü½Å»ýÁ¦, ¸é¿ª°ü¹®¾ïÁ¦Á¦ ¶Ç´Â È­Çпä¹ýÀ» Æ÷ÇÔÇÑ º´¿ë¿ä¹ýµµ ¹ÝÀÀ±â°£À» ¿¬ÀåÇÏ°í »ýÁ¸±â°£À» °³¼±Çϱâ À§ÇØ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ Çõ½ÅÀº ƯÈ÷ Àç¹ß ¹× ÁøÇ༺ EGFR º¯ÀÌ ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ Ä¡·á Àü¸ÁÀ» ³ÐÇô°¡°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ö¿ä¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ȯÀÚ Áý´Ü°ú ÀÇ·á ½Ã½ºÅÛÀº?

EGFR-NSCLC ºÎ¹®Àº µ¹¿¬º¯ÀÌ À¯º´·üÀÌ ³ôÀº µ¿¾Æ½Ã¾Æ ±¹°¡¿¡¼­ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. À̵é Áö¿ª¿¡¼­´Â ÀÏ»óÀûÀÎ ºÐÀÚ ÇÁ·ÎÆÄÀϸµ°ú EGFR ¾ïÁ¦Á¦¸¦ ÀÌ¿ëÇÑ Á¶±â Ä¡·á°¡ ÀϹÝÀûÀÎ ÀÓ»ó °üÇàÀÌ µÇ°í ÀÖ½À´Ï´Ù. À¯·´°ú ¹Ì±¹ÀÇ ÀÇ·á ½Ã½ºÅÛ¿¡¼­ °Ë»ç ÇÁ·ÎÅäÄÝÀÌ Ç¥ÁØÈ­µÇ°í, »óȯ Á¤Ã¥ÀÌ Áö¿øµÊ¿¡ µû¶ó äÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Àα¸ °í·ÉÈ­, Æó¾Ï ¹ßº´·ü Áõ°¡, À¯Àüü °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼º Áõ°¡´Â Àü ¼¼°èÀûÀ¸·Î Àû°Ý ȯÀÚ ¹ß±¼À» Áõ°¡½ÃŰ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

ÇмúÀÇ·á¼¾ÅÍ¿Í ¾ÏÄ¡·áº´¿øÀº ¿¬±¸ ½ÃÇè, Ä¡·á °¡À̵å¶óÀÎ ¾÷µ¥ÀÌÆ®, ±³À° º¸±Þ Ȱµ¿À» ÅëÇØ äÅÃÀ» À̲ô´Â Áß½ÉÀûÀÎ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ È¯ÀÚÀÇ Àνİú Á¤¹Ð Á¾¾çÇп¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Áø´Ü ½ÃÁ¡¿¡ EGFR ½ºÅ©¸®´×À» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÌ °¡Ä¡ ±â¹Ý Ä¡·á¸¦ ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý Ä¡·á·ÎÀÇ ÀüȯÀº ƯÈ÷ °Ç°­ °á°ú¿Í ºñ¿ë È¿À²¼ºÀÌ ±³Â÷ÇÏ´Â ºÐ¾ß¿¡¼­ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù.

EGFR-NSCLC ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

EGFR-NSCLC ½ÃÀåÀÇ ¼ºÀåÀº ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ´ëÁßÈ­, ¾à¹° Çõ½Å, Á¤¹Ð Á¾¾çÇÐ µµÀÔ°ú °ü·ÃµÈ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÁ¤ Áý´Ü¿¡¼­ EGFR µ¹¿¬º¯ÀÌÀÇ ³ôÀº ºñÀ²Àº ±¤¹üÀ§ÇÑ °Ë»ç ¹× Ç¥Àû Ä¡·áÀÇ Ã¤ÅÃÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ³»¼º ¹× ÁßÃ߽Űæ°è Áúȯ¿¡ ´ëÇÑ È¿´ÉÀÌ °³¼±µÈ Â÷¼¼´ë TKIÀÇ °³¹ß·Î Ä¡·á ±â°£ÀÌ ±æ¾îÁö°í ȯÀÚ ¿¹Èİ¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù.

µ¿¹ÝÁø´Ü ¾à¹°ÀÇ ÅëÇÕ°ú À¯Àüü °Ë»ç¿¡ ´ëÇÑ »óȯ Áö¿øÀ¸·Î Ç¥ÀûÈ­ °¡´ÉÇÑ µ¹¿¬º¯ÀÌÀÇ Á¶±â ½Äº°ÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î EGFR ¾ïÁ¦Á¦ ÀÓ»ó½ÃÇèÀÇ È®´ë¿Í ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ¸·Î Ä¡·á ¿É¼ÇÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ±×µ¿¾È Ä¡·á ¿É¼ÇÀÌ ÃæºÐÇÏÁö ¾Ê¾Ò´ø ȯÀÚ±ºÀÇ Ä¡·á ¿É¼ÇÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í Ç¥Àû Ä¡·áÀÇ ÀÓ»óÀû °¡Ä¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÀÇ»çµéÀÇ Ã¤¿ë°ú ½Ã½ºÅÛ Â÷¿øÀÇ ÅëÇÕÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ Á¾ÇÕÀûÀ¸·Î EGFR-NSCLC Ä¡·á ½ÃÀå¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ¿Í Ä¡·áÀÇ ÁøÀüÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¾à¹° À¯Çü(Osimertinib, Erlotinib, Afatinib, Gefitinib, Dacomitinib), À¯Åë ä³Î(¿ÀÇÁ¶óÀÎ, ¿Â¶óÀÎ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market to Reach US$10.1 Billion by 2030

The global market for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) estimated at US$7.5 Billion in the year 2024, is expected to reach US$10.1 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Osimertinib, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Erlotinib segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 8.3% CAGR

The Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global EGFR - Non-Small Cell Lung Cancer (NSCLC) Market - Key Trends & Drivers Summarized

How Is EGFR Status Influencing Treatment Strategies in NSCLC?

Epidermal Growth Factor Receptor (EGFR) mutations are a key biomarker in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma subtypes. These mutations lead to overactivation of EGFR signaling pathways, promoting uncontrolled cell division and tumor growth. Approximately 10-15% of NSCLC patients in Western populations and up to 40% in Asian populations exhibit EGFR mutations, making molecular testing critical for personalized treatment planning.

Identification of EGFR mutations has enabled the use of targeted therapies, notably tyrosine kinase inhibitors (TKIs), which inhibit aberrant EGFR signaling. These drugs have improved progression-free survival and reduced toxicity compared to conventional chemotherapy. First-generation TKIs such as gefitinib and erlotinib have given way to newer agents like osimertinib, which can overcome resistance mutations such as T790M. As a result, EGFR testing is now a standard component of NSCLC diagnosis in clinical oncology workflows.

What Advancements Are Reshaping Targeted Therapy and Resistance Management?

Recent advancements in EGFR-targeted therapy focus on enhancing drug selectivity, overcoming resistance, and minimizing adverse effects. Third-generation TKIs such as osimertinib have shown efficacy in central nervous system metastases and in patients with acquired resistance to earlier therapies. Research is ongoing into fourth-generation inhibitors designed to target uncommon EGFR mutations or compound mutations that current drugs cannot address effectively.

Liquid biopsy technologies are emerging as non-invasive tools to monitor EGFR mutation status and detect resistance mutations in real time. These tools enable dynamic treatment adjustment and reduce reliance on tissue biopsy. Combination therapies involving TKIs and anti-angiogenic agents, immune checkpoint inhibitors, or chemotherapy are also being studied to prolong response duration and improve survival. These therapeutic innovations are expanding the treatment landscape for EGFR-mutated NSCLC, particularly in relapsed and advanced-stage patients.

Which Patient Populations and Healthcare Systems Are Impacting Market Demand?

The EGFR-NSCLC segment is especially significant in East Asian countries where mutation prevalence is high. In these regions, routine molecular profiling and early-stage treatment with EGFR inhibitors are common clinical practices. In Western healthcare systems, adoption is growing as testing protocols become standardized and supported by reimbursement policies. Aging populations, rising lung cancer incidence, and growing access to genomic testing are contributing to increased identification of eligible patients globally.

Academic medical centers and cancer treatment hospitals play a central role in guiding adoption through research trials, updated treatment guidelines, and educational outreach. Patient awareness of genetic testing and demand for precision oncology is increasing, further promoting EGFR screening at the point of diagnosis. As healthcare systems prioritize value-based care, the shift toward biomarker-driven treatment is becoming more prominent, especially where health outcomes and cost efficiency intersect.

What Is Driving Growth in the EGFR - NSCLC Market?

Growth in the EGFR-NSCLC market is driven by several factors related to biomarker prevalence, drug innovation, and precision oncology uptake. High rates of EGFR mutations in specific populations are supporting broad testing and targeted therapy adoption. Development of next-generation TKIs with improved efficacy against resistant and CNS-involved disease is expanding treatment duration and improving patient outcomes.

Integration of companion diagnostics and reimbursement support for genomic testing are enhancing early identification of targetable mutations. Expansion of clinical trials and regulatory approvals for novel EGFR inhibitors are increasing treatment options, especially in previously under-addressed patient subsets. Rising awareness of personalized medicine and the clinical value of targeted therapies is strengthening physician adoption and system-level integration. These factors are collectively driving sustained investment and therapeutic advancement in the EGFR-NSCLC treatment market.

SCOPE OF STUDY:

The report analyzes the Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Osimertinib, Erlotinib, Afatinib, Gefitinib, Dacomitinib); Distribution Channel (Offline Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â